Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III
Accro Bioscience (Suzhou) Limited, better known as Accropeutics, announced on Sept 8, 2026 that its...
Accropeutics
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has...
Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment
Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...
Accropeutics Doses First Patient in AC-101 Phase Ib UC Study
Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...